Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -7620.53% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-7620.53%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Nautilus Biotechnolgy, Inc.
Market Cap
$227.79M
EBITDA Margin
-7620.53%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$227.60M
EBITDA Margin
-25.05%
TTM Avg
-32.88%
3Y Avg
-63.97%
5Y Avg
-61.52%
Market Cap
$231.73M
EBITDA Margin
-1029.09%
TTM Avg
-1029.09%
3Y Avg
-1029.09%
5Y Avg
-1029.09%
Market Cap
$230.22M
EBITDA Margin
-43.93%
TTM Avg
-56.69%
3Y Avg
-115.93%
5Y Avg
-139.79%
Market Cap
$233.28M
EBITDA Margin
-163095.33%
TTM Avg
-97357.05%
3Y Avg
-88166.59%
5Y Avg
-88166.59%
Market Cap
$235.43M
EBITDA Margin
37.26%
TTM Avg
38.63%
3Y Avg
43.69%
5Y Avg
46.28%
Market Cap
$219.48M
EBITDA Margin
-252.79%
TTM Avg
-276.80%
3Y Avg
-348.01%
5Y Avg
-340.44%
Market Cap
$238.16M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $227.79M | -7620.53% | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | -25.05% | -32.88% | -63.97% | -61.52% |
| BioAge Labs Inc. (BIOA)vs › | $231.73M | -1029.09% | -1029.09% | -1029.09% | -1029.09% |
| MacroGenics, Inc. (MGNX)vs › | $230.22M | -43.93% | -56.69% | -115.93% | -139.79% |
| Vogenx Inc. (VOGX)vs › | $224.23M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $233.28M | -163095.33% | -97357.05% | -88166.59% | -88166.59% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.43M | 37.26% | 38.63% | 43.69% | 46.28% |
| Profound Medical Corp. (PROF)vs › | $219.48M | -252.79% | -276.80% | -348.01% | -340.44% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $238.16M | 10.49% | 1.20% | -4.19% | -40.04% |
| Quantum-Si incorporated (QSI)vs › | $239.35M | -3813.88% | -3607.01% | -5701.50% | -5701.50% |
Gross Margin
0.0%
EBITDA Margin
-7620.5%
Operating Margin
0.0%
Net Margin
-29747.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -7620.53% |
